Download MendeleyAdvancing TET Inhibitor Development: From Structural Insights to Biological Evaluation.
Willems, S., Maksumic, L., Niggenaber, J., Lin, T.C., Schulz, T., Weisner, J., Sievers, S., Muller, M.P., Summerer, D., Rauh, D.(2025) ACS Med Chem Lett 16: 804-810
- PubMed: 40365382
- DOI: https://doi.org/10.1021/acsmedchemlett.5c00042
- Primary Citation of Related Structures:
9HXV - PubMed Abstract:
Ten-eleven translocation (TET) methylcytosine dioxygenases are part of the epigenetic regulatory machinery that erases DNA methylation. Aberrant TET activities are frequently found in hematopoietic malignancies, where loss of TET2 function leads to DNA hypermethylation. A comprehensive understanding of the biological role of TETs is essential to elucidate disease pathogenesis and identify novel therapeutic strategies. We present a robust pipeline integrating protein X-ray crystallography, molecular modeling, and pharmacophore analysis to advance the current TET inhibitor development. In addition, we have synthesized and evaluated a series of 8-hydroxyquinoline (8-HQ) derivatives, demonstrating their potential as chemical tools to explore TET function further. These findings lay the groundwork for a TET-centered therapeutic approach.
- Department of Chemistry and Chemical Biology, TU Dortmund University and Drug Discovery Hub Dortmund (DDHD) am Zentrum für integrierte Wirkstoffforschung (ZIW), Otto-Hahn-Str. 4a, 44227 Dortmund, Germany.
Organizational Affiliation:
